TC-5619: An alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia
- 1 October 2009
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 78 (7) , 803-812
- https://doi.org/10.1016/j.bcp.2009.05.030
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- Serotonergic hyperinnervation and effective serotonin blockade in an FGF receptor developmental model of psychosisSchizophrenia Research, 2009
- Atypical antipsychotics as noncompetitive inhibitors of α4β2 and α7 neuronal nicotinic receptorsNeuropharmacology, 2009
- Extrapyramidal side-effects of antipsychotics in a randomised trialThe British Journal of Psychiatry, 2008
- Allosteric modulation of α7 nicotinic receptors selectively depolarizes hippocampal interneurons, enhancing spontaneous GABAergic transmissionEuropean Journal of Neuroscience, 2008
- An Allosteric Modulator of the α7 Nicotinic Acetylcholine Receptor Possessing Cognition-Enhancing Properties in VivoThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Estimation of both the potency and efficacy of α7 nAChR agonists from single-concentration responsesLife Sciences, 2005
- Comparative pharmacology of rat and human α7 nAChR conducted with net charge analysisBritish Journal of Pharmacology, 2002
- Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophreniaNature Neuroscience, 2002
- The α7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophreniaJournal of Chemical Neuroanatomy, 2000
- AR-R 17779, an α7 nicotinic agonist, improves learning and memory in ratsBehavioural Pharmacology, 1999